The Engineer

AstraZeneca outlines investment plans for UK

News

AstraZeneca plans to invest £450m at its manufacturing site in Speke, Liverpool for the research, development, and manufacture of vaccines.

AdobeStock

The investment is part of a £650m package that will see the biopharmaceutical company invest a further £200m into expanding its presence in Cambridge’s life sciences cluster.

In a statement, AstraZeneca CEO Sir Pascal Soriot, said: “AstraZeneca’s planned investment would enhance the UK’s pandemic preparedness and demonstrates our ongoing confidence in UK life sciences. We will continue to support the UK in driving innovation and patient access, building on the strong foundations which have been put in place." 

The company’s Speke facility is planned to work in tandem with the UK Health Security Agency (UKHSA)’s Porton Down site in Salisbury on developing and evaluating vaccines. 

Investment into Cambridge will see the development of a second facility adjacent to AstraZeneca’s £1.1bn global R&D Discovery Centre and the creation of around 1,000 jobs.

The company will also open a new manufacturing facility for one of its cancer medicines in Macclesfield later in 2024, following the announcement of a £380m investment in 2021. 

Register now to continue reading

Thanks for visiting The Engineer. You’ve now reached your monthly limit of news stories. Register for free to unlock unlimited access to all of our news coverage, as well as premium content including opinion, in-depth features and special reports.  

Benefits of registering

  • In-depth insights and coverage of key emerging trends

  • Unrestricted access to special reports throughout the year

  • Daily technology news delivered straight to your inbox

Register
Or continue by

Signing in with your registered email address

inward investment